Figure 4
NOVA compounds selectively activate the MOP in the 35S-GTPγS coupling assay. (A) Summary agonist concentration curves for the NOVA compounds and a positive control agonist (DAMGO for MOP; SNC80 for DOP; U50,488 for KOP) in 35S-GTPγS coupling shown. All compounds were normalized to the stimulation caused by the positive control (100%) and vehicle (0%) and reported as the mean ± SEM from n = 3 independent experiments. (B) The potencies (EC50) and efficacies (EMax) of each NOVA compound and positive control were calculated in each independent experiment (n = 3), then reported as the mean ± SEM. The EMax was reported as a percent of stimulation caused by the positive control, which had a defined EMax of 100%. For the DOP and KOP, EMax values in parentheses report the maximum stimulation at 10 μM of compound, not the fully defined top of the agonist curve, as these curves are incomplete at 10 μM.
